Chen Fu
Impact in
- Aging top 10%
-
- RNA Interference and Gene Delivery
- Epigenetics and DNA Methylation
Papers in
-
- CRISPR and Genetic Engineering 2
- Oncology 10
- HER2/EGFR in Cancer Research 3
- CAR-T cell therapy research 3
- Cancer Immunotherapy and Biomarkers 2
- Co-authors
- Zhaojin Yu (7 shared papers)Yuxi Miao (3 shared papers)Lifeng Yu (3 shared papers)Minjie Wei (3 shared papers)Xinli Liu (1 shared paper)Anthony Wynshaw‐Boris (4 shared papers)Xudong Liao (2 shared papers)Keiki Sugi (2 shared papers)
- Journals
- Poultry Science (2 papers)Acta Pharmaceutica Sinica B (2 papers)Human Molecular Genetics (2 papers)Proceedings of the National Academy of Sciences (2 papers)BMC Cancer (2 papers)
- Partner nations
- ChinaUnited StatesSouth Korea
In The Last Decade
Chen Fu
38 papers receiving 848 citations
Chen Fu's Hit Papers
Peers
Comparison fields: 5 of 110
- Aging 19
- Molecular Biology 426
- Endocrine and Autonomic Systems 39
- Oncology 156
- Cancer Research 83
Countries citing papers authored by Chen Fu
This map shows the geographic impact of Chen Fu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chen Fu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chen Fu more than expected).
Fields of papers citing papers by Chen Fu
This network shows the impact of papers produced by Chen Fu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chen Fu. The network helps show where Chen Fu may publish in the future.
Co-authors
The 25 scholars most cited alongside Chen Fu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 45 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2018 | 147 | |
| 2 | Peptide–drug conjugates (PDCs): a novel trend of research and development on targeted therapy, hype or hope? Hit paper breakdown → | 2022 | 133 |
| 3 | 2017 | 56 | |
| 4 | 2004 | 53 | |
| 5 | 2013 | 47 | |
| 6 | 2017 | 41 | |
| 7 | 2016 | 38 | |
| 8 | 2021 | 34 | |
| 9 | Antibody–Drug Conjugates (ADCs): current and future biopharmaceuticals Hit paper breakdown → | 2025 | 33 |
| 10 | 2020 | 26 | |
| 11 | 2024 | 25 | |
| 12 | 2018 | 25 | |
| 13 | 2024 | 21 | |
| 14 | 2023 | 16 | |
| 15 | 2020 | 16 | |
| 16 | 2021 | 15 | |
| 17 | 2003 | 14 | |
| 18 | 2017 | 13 | |
| 19 | 2019 | 11 | |
| 20 | 2019 | 11 |
About Chen Fu
Chen Fu is a scholar working on Molecular Biology, Oncology, Epidemiology, Immunology and Pulmonary and Respiratory Medicine, having authored 45 papers that have together received 860 indexed citations. Recurring topics across this work include Ferroptosis and cancer prognosis (4 papers), HER2/EGFR in Cancer Research (3 papers), Immunotherapy and Immune Responses (3 papers), Monoclonal and Polyclonal Antibodies Research (3 papers), Autophagy in Disease and Therapy (3 papers), CAR-T cell therapy research (3 papers), CRISPR and Genetic Engineering (2 papers) and Cancer Immunotherapy and Biomarkers (2 papers). The work is most often cited by research in Aging (19 citations), Molecular Biology (426 citations), Endocrine and Autonomic Systems (39 citations), Oncology (156 citations) and Cancer Research (83 citations). Chen Fu has collaborated with scholars based in China, United States and South Korea. Frequent co-authors include Zhaojin Yu, Yuxi Miao, Lifeng Yu, Minjie Wei, Xinli Liu, Anthony Wynshaw‐Boris, Xudong Liao, Keiki Sugi, Rongli Zhang and Yuyan Shen. Their work appears in journals such as Poultry Science, Acta Pharmaceutica Sinica B, Human Molecular Genetics, Proceedings of the National Academy of Sciences and BMC Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.